Antisense Therapeutics Ltd
Records under this name other than the patents Antisense Therapeutics Ltd holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 3 patents it holds.
Back to Antisense Therapeutics Ltd
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,759,314 | Methods for treating multiple sclerosis using antisense oligonucleotides Lapsed on the fee record Ended Jun 24, 2026 · From the USPTO record | Lapsed on the fee record | Ended Jun 24, 2026 | From the USPTO record |
| US 9,885,048 | Method for reducing circulating leukocytes in a human subject Lapsed on the fee record Ended Feb 6, 2026 · From the USPTO record | Lapsed on the fee record | Ended Feb 6, 2026 | From the USPTO record |
| US 9,821,034 | Combination therapy Lapsed on the fee record Ended Nov 21, 2025 · From the USPTO record | Lapsed on the fee record | Ended Nov 21, 2025 | From the USPTO record |
| US 9,717,778 | Combination therapy Lapsed on the fee record Ended Aug 1, 2025 · From the USPTO record | Lapsed on the fee record | Ended Aug 1, 2025 | From the USPTO record |
| US 8,415,314 | Methods for Treating Multiple Sclerosis Using Antisense Oligonucleotides Lapsed on the fee record Ended Apr 9, 2025 · High confidence | Lapsed on the fee record | Ended Apr 9, 2025 | High confidence |
| US 8,299,039 | Modulation of Growth Hormone Receptor Expression and Insulin-Like Growth Factor Expression Formerly held Lapsed on the fee record Ended Oct 30, 2024 · High confidence | Lapsed on the fee record | Ended Oct 30, 2024 | High confidence |
| US 8,623,836 | Modulation of Growth Hormone Receptor Expression and Insulin-Like Growth Factor Expression Term ended Term ended Apr 10, 2024 · High confidence | Term ended | Term ended Apr 10, 2024 | High confidence |
| US 9,371,530 | Modulation of growth hormone receptor expression and insulin-like growth factor expression Term ended Term ended Feb 27, 2024 · From the USPTO record | Term ended | Term ended Feb 27, 2024 | From the USPTO record |
| US 9,988,635 | Modulation of growth hormone receptor expression and insulin-like growth factor expression Term ended Ended no later than Feb 27, 2024 · From the USPTO record | Term ended | Ended no later than Feb 27, 2024 | From the USPTO record |
| US 8,637,484 | Modulation of Growth Hormone Receptor Expression and Insulin-Like Growth Factor Expression Term ended Term ended Feb 26, 2024 · High confidence | Term ended | Term ended Feb 26, 2024 | High confidence |